EYPT - Company ID 0001314102
The table below shows EyePoint Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $77.71M | $74.58M | $71.14M | $85.16M | $79.83M | $90.77M |
| Short-term investments | $144.83M | $129.44M | $184.59M | $233.04M | $173.96M | $189.48M |
| Receivables | - | - | - | - | - | - |
| Inventory | $1.25M | $2.11M | $2.68M | $2.13M | $2.81M | $3.67M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $249.50M |
| $216.11M |
| $265.25M |
| $326.98M |
| $268.55M |
| $294.93M |
| Property, plant & equipment | $9.48M | $8.86M | $8.76M | $8.04M | $8.39M | $6.90M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $288.22M | $251.69M | $301.15M | $362.56M | $300.92M | $324.25M |
| Accounts payable | $18.81M | $10.08M | $19.68M | $16.42M | $7.34M | $14.30M |
| Total current liabilities | $37.46M | $30.09M | $33.17M | $41.68M | $48.79M | $62.10M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $57.74M | $51.51M | $55.14M | $64.17M | $82.18M | $95.94M |
| Retained earnings | -$1.19B | -$1.04B | -$977.64M | -$918.21M | -$831.62M | -$802.26M |
| Total equity | $230.47M | $200.18M | $246.01M | $298.40M | $218.73M | $228.31M |